Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
- Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise
- 3Q23 DAYBUE™ (trofinetide) net product sales of $66.9 million
- 3Q23 NUPLAZID® (pimavanserin) net product sales of $144.8 million
https://www.businesswire.com/news/home/20231102863530/en/
- Forums
- ASX - By Stock
- NEU
- DAYBUE BOOOOOM !!!!!!!!!!!
DAYBUE BOOOOOM !!!!!!!!!!!
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.14 |
Change
-1.960(9.75%) |
Mkt cap ! $2.378B |
Open | High | Low | Value | Volume |
$19.86 | $19.99 | $17.97 | $7.095M | 379.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 78 | $18.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.15 | 66 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 86 | 18.110 |
3 | 66 | 18.100 |
3 | 78 | 18.090 |
2 | 163 | 18.080 |
2 | 155 | 18.070 |
Price($) | Vol. | No. |
---|---|---|
18.130 | 262 | 3 |
18.140 | 76 | 3 |
18.150 | 213 | 3 |
18.160 | 365 | 4 |
18.170 | 182 | 2 |
Last trade - 11.18am 09/05/2024 (20 minute delay) ? |
|
|||||
Last
$18.73 |
  |
Change
-1.960 ( 6.77 %) |
|||
Open | High | Low | Volume | ||
$19.88 | $19.88 | $17.97 | 108680 | ||
Last updated 11.37am 09/05/2024 ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online